Published in Lab Business Week, July 23rd, 2006
Doral is a nonnarcotic, selective benzodiazepine receptor agonist for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings.
James Fares, Questcor's president and CEO, commented on Questcor's goal to build a high value, low risk pipeline of medically important CNS products.
"With the strong success we are seeing from our efforts to grow Acthar Gel, we are ready to turn to the next stage of our evolution into a leading CNS focused specialty pharmaceutical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.